When the Drug Fits: Examining Targeted Cancer Therapy
Februrary 6, 2012•15 min
Hosted by: Bruce Bloom Guest: David Fisher Imatinib mesylate was initially approved for chronic myeloid leukemia. It has also been used against gastrointestinal cancer and melanoma. What are the implications of broadening the application of this targeted cancer drug for the way that cancers are diagnosed and classified, and what will the impact be on clinical trial design? Are we getting closer to the end of tumor-typing by location?